Another key plank of Amgen’s remarkable growth in the 1990s and early 2000s was through mergers and acquisitions. It focused on other innovative biotechnology companies, acquiring Synergen in ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Chief executive Robert Bradway said the acquisition was “an exciting milestone” for Amgen and will build on the company’s “strong momentum” in its core business. The main condition set ...

Our analysis of options history for Amgen AMGN revealed 19 unusual trades ... and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio ...

Looking at options history for Amgen AMGN we detected 14 trades ... and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis.

Amgen discovers, develops ... anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc ...

THOUSAND OAKS, Calif., March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The ...

March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN ) today announced ... sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon ...